Summary
This prediction ended on 03.04.19 with a price of €25.00. The prediction had a final performance of 14.89%. elbawind has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | -4.062% | -4.062% | -44.551% | -71.668% |
| iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
| iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
| iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
| iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
Comments by elbawind for this prediction
In the thread Evotec AG diskutieren
Stabilisierung setzt sich fort
Die Kurssteigerungen der letzten Wochen sollten sich fortsetzen, da die Höchststände vom Dezember überschritten worden sind und die Shortseller wohl endgültig die Szene verlassen haben. Wichtig für eine positive Einschätzung ist auch die Tatsache, daß die Topkonstellation von Anfang Dez. überschritten worden ist, dh. hier befindet sich ab sofort eine stabile Unterstützung!